SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles...
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in...